EUREPA V 1/0.2 (Repaglinide (1mg) + Voglibose (0.2mg))

Eurepa-V 1/0.2 Tablet is a formulation that combines two active ingredients designed to manage type 2 diabetes mellitus. This medication plays a crucial role in regulating elevated blood glucose levels that typically rise after meals. It is especially beneficial for individuals whose blood sugar remains high despite adhering to a specific diet and using other comparable treatments. It is important to take this tablet immediately following a meal, and the appropriate dosage will be determined by your healthcare provider. Patients should not discontinue use without consulting their doctor, as doing so could lead to increased blood sugar levels and heighten the risk of severe complications, including damage to the kidneys and vision loss. If a dose is missed, it should not be taken between meals; instead, wait for the next scheduled meal to take the usual dose. It is vital not to double up on doses to compensate for a missed one. This medication should be seen as part of a comprehensive management plan, which should also incorporate a nutritious diet, consistent physical activity, and weight management strategies as recommended by your physician. Common adverse reactions may include flatulence, diarrhea, stomach discomfort, episodes of hypoglycemia, and skin rashes. While these effects are generally temporary and resolve independently, it is advisable to seek medical advice if they persist or worsen. Regular monitoring of blood glucose levels is essential during treatment.